CAS
TSHA icon

CTC Alternative Strategies’s Taysha Gene Therapies TSHA Stock Holding History

CTC Alternative Strategies’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-29,800
Closed -$85.5K – 275
2024
Q1 		$85.5K Buy
+29,800
New +$62.1K 0.05% 83

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

CTC Alternative Strategies's TSHA Position: Q2 2024 in Review

CTC Alternative Strategies sold out of Taysha Gene Therapies (TSHA) in Q2 2024, closing a stake of 29,800 shares — an estimated $85.5K sold.

CTC Alternative Strategies first reported a position in TSHA in Q1 2024 and held it in 1 quarter. The position peaked at $85.5K in Q1 2024. 107 funds tracked by Wall St. Rank hold TSHA as of Q2 2024.

  • CTC Alternative Strategies reported no remaining Taysha Gene Therapies position as of Q2 2024 after selling out during the quarter.
  • CTC Alternative Strategies sold 29,800 Taysha Gene Therapies shares in Q2 2024, an estimated $85.5K.
  • CTC Alternative Strategies first reported a position in Taysha Gene Therapies in Q1 2024 and held it in 1 quarter.
  • CTC Alternative Strategies's Taysha Gene Therapies position peaked at $85.5K in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2024.

Based on CTC Alternative Strategies's 13F filing for Q2 2024, filed 2 Aug 2024.